Understanding Defense Acquisition, and More from CRS
Noteworthy new and updated reports from the Congressional Research Service that Congress has not made publicly available include the following.
Defense Acquisitions: How DOD Acquires Weapon Systems and Recent Efforts to Reform the Process, January 2, 2013
U.S. Periods of War and Dates of Current Conflicts, December 28, 2012
The Army’s Ground Combat Vehicle (GCV) Program: Background and Issues for Congress, January 2, 2013
Marine Corps Amphibious Combat Vehicle (ACV) and Marine Personnel Carrier (MPC): Background and Issues for Congress, January 2, 2013
Joint Light Tactical Vehicle (JLTV): Background and Issues for Congress, January 2, 2013
Comprehensive Nuclear-Test-Ban Treaty: Background and Current Developments, January 2, 2013
Improper Payments and Recovery Audits: Legislation, Implementation, and Analysis, January 2, 2013
The Purple Heart: Background and Issues for Congress, December 31, 2012
Geoengineering: Governance and Technology Policy, January 2, 2013
Is Biopower Carbon Neutral?, January 2, 2013
Unemployment Insurance: Programs and Benefits, December 31, 2012
Federal Benefits and the Same-Sex Partners of Federal Employees, December 21, 2012
The Protection of Lawful Commerce in Arms Act: An Overview of Limiting Tort Liability of Gun Manufacturers, December 20, 2012
The FHA Single-Family Mortgage Insurance Program: Financial Status and Related Current Issues, December 21, 2012
Permanent Legal Immigration to the United States: Policy Overview, December 17, 2012
Inauguration Security: Operations, Appropriations, and Issues for Congress, December 17, 2012
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.
While the U.S. has made significant advancements and remained a global leader in biotechnology over the past decade, the next four years will be critical in determining whether it can sustain that leadership.
As the efficacy of environmental laws has waned, so has their durability. What was once a broadly shared goal – protecting Americans from environmental harm – is now a political football, with rules that whipsaw back and forth depending on who’s in charge.